Next Article in Journal
Prospective Investigation of 18FDG-PET/MRI with Intravoxel Incoherent Motion Diffusion-Weighted Imaging to Assess Survival in Patients with Oropharyngeal or Hypopharyngeal Carcinoma
Next Article in Special Issue
Platelet-Based Liquid Biopsies through the Lens of Machine Learning
Previous Article in Journal
Undifferentiated Pancreatic Carcinomas, Clinical Features and Therapeutic Options: What We Know
Previous Article in Special Issue
Analysis of the Risk of Oral Squamous Cell Carcinoma in Patients with and without Recurrent Aphthous Stomatitis: A Retrospective Evaluation of Real-World Data of about 150,000 Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 14
Issue 24
10.3390/cancers14246103
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Systematic Investigation of the Multifaceted Role of SOX11 in Cancer

by
Qingqing Sun
1,2,
Jun Du
3,
Jie Dong
2,
Shuaikang Pan
2,
Hongwei Jin
1,
Xinghua Han
1,2,* and
Jinguo Zhang
2,*
1
Department of Medical Oncology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei 230001, China
2
Department of Medical Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China
3
Department of Pathology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China
*
Authors to whom correspondence should be addressed.
Cancers 2022, 14(24), 6103; https://doi.org/10.3390/cancers14246103
Submission received: 4 October 2022 / Revised: 23 November 2022 / Accepted: 5 December 2022 / Published: 12 December 2022
(This article belongs to the Special Issue Bioinformatics in Cancer Diagnostics and Screening)
Browse Figures
Review Reports Versions Notes

Abstract

:

Simple Summary

The transcription factor SOX11 is a member of the SRY box-containing family. Recently, SOX11 research has shifted from embryogenesis to cancer development. Nevertheless, the roles of SOX11 in different cancer types remain controversial. Here, we systematically explored the characteristics of SOX11 by multiple omics analyses. Aberrant SOX11 expression has been observed in many types of human malignant tumors. Moreover, SOX11 expression could serve as an indicator of survival outcomes, tumor progression and cellular immune infiltration. Our work highlights the diverse role of SOX11 in different types of tumors, which points out several directions for future prospective studies on SOX11 in cancer.

Abstract

SRY-box transcription factor 11 (SOX11), as a member of the SOX family, is a transcription factor involved in the regulation of specific biological processes and has recently been found to be a prognostic marker for certain cancers. However, the roles of SOX11 in cancer remain controversial. Our study aimed to explore the various aspects of SOX11 in pan-cancer. The expression of SOX11 was investigated by the Genotype Tissue-Expression (GTEX) dataset and the Cancer Genome Atlas (TCGA) database. The protein level of SOX11 in tumor tissues and tumor-adjacent tissues was verified by human pan-cancer tissue microarray. Additionally, we used TCGA pan-cancer data to analyze the correlations among SOX11 expression and survival outcomes, clinical features, stemness, microsatellite instability (MSI), tumor mutation burden (TMB), mismatch repair (MMR) related genes and the tumor immune microenvironment. Furthermore, the cBioPortal database was applied to investigate the gene alterations of SOX11. The main biological processes of SOX11 in cancers were analyzed by Gene Set Enrichment Analysis (GSEA). As a result, aberrant expression of SOX11 has been implicated in 27 kinds of cancer types. Aberrant SOX11 expression was closely associated with survival outcomes, stage, tumor recurrence, MSI, TMB and MMR-related genes. In addition, the most frequent alteration of the SOX11 genome was mutation. Our study also showed the correlations of SOX11 with the level of immune infiltration in various cancers. In summary, our findings underline the multifaceted role and prognostic value of SOX11 in pan-cancer.

1. Introduction

While new treatment strategies have been developed, cancer is still a significant cause of mortality worldwide. According to statistics, in China, an estimated 4,820,000 new cancer cases and 3,210,000 cancer deaths occurred in 2022 [1]. Molecular biomarkers, which can be sensitive enough to detect initial malignant transformations, have always been a prime focus of cancer research. The SRY-related HMG-box 11 transcription factor is one of the members of the SOX gene family that possess a highly conserved high mobility group (HMG) sequence [2]. According to the degree of homology of their domains, SOX genes in humans are classified into eight groups [3]. Together with SOX4 and SOX12, SOX11 is a subgroup of subgroup C [4], located on chromosome 2p25.3 [5]. They share a well-conserved C-terminal region [6]. SOX11 regulates progenitor and stem cell behavior and often acts in regulating developmental processes, including neurogenesis and skeletogenesis [7].
SOX11 is a protein-coding gene that plays a role in transcriptional regulation after forming a protein complex with other proteins [8,9]. Recently, various novel epigenetic regulatory mechanisms of SOX11 have also been revealed [10,11]. SOX11 is primarily expressed in various tissues of humans and mice, including the nervous system, gastrointestinal tract, lung, spleen, pancreas, kidneys and gonads [12,13,14]. Research on SOX11 has shifted from its role in embryogenesis to disease development. In particular, the function of SOX11 in carcinogenesis has become a major focus of interest. In many cancers, dysfunctional expression of SOX11 has been correlated with increased cancer cell survival, inhibition of cell differentiation and tumor progression [15]. Nevertheless, in a limited number of malignancies, SOX11 has also been identified to function as a tumor suppressor [16].
Previous studies have shown that the expression levels of SOX11 vary in different cancer types. For example, a high level of SOX11 mRNA can be detected in many types of tumors, including breast cancer [17], mantle cell lymphoma [18], epithelial ovarian cancer [19] and hepatocellular carcinoma [20]. In contrast, a low expression of SOX11 was frequently observed in other cancers, such as nasopharyngeal carcinoma (NPC) [21], prostate cancer [22], gastric cancer (GC) [23] and bladder cancer [24]. Moreover, SOX11 plays diverse roles in a variety of types of cancer. SOX11 has been described as a key oncogenic factor in mantle cell lymphoma (MCL) [25]. A high level of SOX11 expression is associated with poor overall survival (OS) and increased formation of metastasis in breast cancer patients [26,27]. SOX11 can promote invasive transition in vivo, confirming its role in promoting the progression of DCIS to invasive breast cancer [28]. However, SOX11 has been reported to act as a potential tumor suppressor that is down-regulated in prostate cancer and overexpression of SOX11 suppresses migration and invasion in prostate cancer cells in vitro [22]. To date, studies on SOX11 are limited by a single cancer type. Therefore, a systematic investigation the role of SOX11 in cancer is required.
To reveal the role of SOX11 in pan-cancer, we systematically integrated multiple databases from the perspective of bioinformatics. In this study, we comprehensively explored the expression of SOX11 in normal tissues and its corresponding cancer tissues using the Genotype-Tissue Expression (GTEX) and The Cancer Genome Atlas (TCGA) dataset. A tissue microarray was used to verify the difference in SOX11 expression among normal tissues, tumor tissues and corresponding tumor-adjacent tissues. The prognostic value of SOX11 in predicting survival outcomes was also evaluated. Then, the potential relationships between SOX11 expression and clinicopathological phenotypes, stemness score, TMB, MSI, MMR-related genes and tumor immune microenvironment were further explored. In addition, GSEA was used to clarify the biological function of SOX11 in pan-cancer. Overall, this study highlights the multifaceted role of SOX11 in a variety of cancers, which may provide a theoretical basis for using SOX11 as a prognostic biomarker in cancer.

2. Materials and Methods

2.1. Data Processing and SOX11 Expression Analysis

Transcriptome data and clinical features of TCGA pan-cancer were downloaded from the UCSC XENA (https://xena.ucsc.edu/, accessed on 6 August 2022). Gene expression data for 31 normal human tissues were obtained from the GTEX website (https://www.gtexportal.org/, accessed on 6 August 2022). The mRNA expression of SOX11 was extracted using Perl scripts (Version 5.30.0.1, http://strawberryperl.com/, accessed on 6 August 2022). The Wilcoxon rank-sum test was used to examine differences in SOX11 expression. All statistical analyses and plotting of the results were performed using R version 4.0.2 software (https://www.Rproject.org, accessed on 10 July 2022).

2.2. Tissue Microarray and Human Protein Atlas (HPA) Database

Human pan-cancer tissue arrays (Cat# HOrgC120PG04, Shanghai Outdo Biotech Co., Ltd., Shanghai, China) were analyzed for the protein expression of SOX11 by immunohistochemistry. Research ethics approval was granted by the Ethics Committee of Shanghai Outdo Biotech Co., Ltd. (protocol code SHYJS-CP-1901007 and date of approval: 2 January 2019). The anti-SOX11 antibody (1:500 dilution, #ab229185) was purchased from Abcam (Abcam, UK). The tissue microarray (HOrgC120PG04) contains 120 paraffin-embedded tissue samples. Among them, 21 samples were either invalid or missing. A total of 99 valid samples were ultimately obtained, which included 45 malignant tumor tissues and 54 adjacent tissues of cancer or normal tissues. We calculated the SOX11 immunostaining score by multiplying the percentage of positively stained cells with the intensity of staining. In this study, the high expression of SOX11 was explained by a staining index score of ≤6, while the low expression of SOX11 was defined as a staining index of >6. The protein level of SOX11 in cancer and corresponding normal tissues was also validated in Human Protein Atlas (HPA) database (https://www.proteinatlas.org/, accessed on 4 September 2022).

2.3. Relationship of SOX11 Expression with Survival Outcomes and Clinical Characteristics

We acquired the survival and clinical data of pan-cancer from the UCSC XENA repository. Kaplan–Meier method and Cox proportional hazards model were adopted to assess the correlations between SOX11 expression and OS, progression-free survival (PFS), disease-specific survival (DSS) and disease-free survival (DFS). Kaplan–Meier survival curves were generated by the “survival” and “survminer” packages. Here, we also explored the associations of SOX11 expression with tumor stage and tumor status.

2.4. Genomic Alterations of SOX11 in Pan-Cancer and Breast Cancer

SOX11 gene alterations in TCGA pan-cancer datasets were examined by the cBioPortal database (http://www.cbioportal.org/, accessed on 10 September 2022) [29]. The “Oncoprint” and “Cancer Type Summary” tabs were used to explore the genetic alterations of SOX11. The mutated site information of SOX11 was analyzed by the “Mutations” module in the database. The effect of SOX11 alterations on disease-free survival and disease-specific survival was investigated using the “Comparison/Survival” module.

2.5. Analysis of SOX11 Expression with Stemness Score and EMT-Related Genes in Cancers

The RNA stemness score (RNAss) or DNA stemness score (DNAss) based on mRNA expression could be used to assess tumor stemness [30]. We intersected SOX11 gene expression data with RNAss or DNAss to calculate the correlation coefficient. The results were visualized with the corrplot R package. In addition, correlation analysis between SOX11 expression and cancer stem cell marker genes and EMT-related genes was further determined. A heatmap graph was created using the R packages “reshape2” and “RColorBrewer.”

2.6. Analysis of SOX11 Expression with TMB and MSI in Pan-Cancer

Biomarkers such as TMB and MSI are considered predictive of immune checkpoint inhibitor sensitivity [31,32]. We first calculated the TMB scores of each sample using TCGA pan-cancer mutation data. The MSI data in this study were obtained from Bonneville et al.’s pan-cancer study [33]. The correlations between SOX11 expression and TMB, MSI were tested using Spearman’s coefficient. The results were presented in radar plots by the R-package “fmsb.” A defect in the DNA mismatch repair system (MMR) was defined as the presence of microsatellite instability (MSI-H) and/or the lack of hMLH1 protein expression [34]. We thus explored the relationship between SOX11 expression and MMR-related genes in cancers. The heatmaps were generated using the R packages “RColorBrewer” and “reshape2”.

2.7. Relationship of SOX11 Expression with the Tumor Immune Microenvironment in Pan-Cancer

In this study, the StromalScore and ImmuneScore were calculated using the Estimation of Stromal and Immune Cells in Malignant Tumors using the expression data (ESTIMATE) algorithm to evaluate the level of estimated stromal and immune cells [35]. The corrplot R package was used to visualize Spearman rank correlation tests. Immune cell infiltration analysis was conducted using the CIBERSORT algorithm [36].

2.8. Gene Set Enrichment Analysis (GSEA)

To explore the potential biological functions of SOX11 cancer, GSEA was performed using the R-packages “enrichplot”, “org.Hs.eg.db”, “clusterProfiler”, “DOSE”, and “limma”. The gene signatures of Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were compiled from the MSigDB database (https://www.gsea-msigdb.org/gsea/downloads.jsp, accessed on 12 August 2022).

2.9. Statistical Analysis

In this study, R statistical software version 4.1.1 (Vienna, Austria) was used to perform statistical analyses. The Cox proportional hazard regression model was used to estimate the hazard ratio (HR). Survival curves were compared using the Kaplan-Meier method and a log-rank test. Spearman rank correlation was used for the correlation analysis. Fisher’s exact test was applied to compare SOX11 expression between cancer and normal tissues. The statistical significance of the results was defined as a p-value less than 0.05 (* p < 0.05, ** p < 0.01, *** p < 0.001).

3. Results

3.1. Expression Levels of SOX11 in Normal Tissues and Pan-Cancer

We first investigated the expression of SOX11 in the normal physiological state of the body using the GTEX dataset. The results showed that SOX11 was highly expressed in the brain, colon, heart, pituitary and spleen tissues, while a low or undetectable level of SOX11 expression was found in other human tissues (Figure 1A). In Figure 1B, we explored the difference in SOX11 expression between male and female normal tissues, and a significant sex difference in SOX11 expression was found only in breast tissues. Then RNA-seq data from the TCGA database were applied to analyze the expression of SOX11 in various cancers. Aberrant expression of SOX11 was detected in a total of 27 cancers. SOX11 was upregulated in adrenocortical carcinoma (ACC), bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), cholangiocarcinoma (CHOL), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), brain lower grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), prostate adenocarcinoma (PRAD), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), testicular germ cell tumors (TGCT), thyroid carcinoma (THCA), thymoma (THYM), uterine corpus endometrial carcinoma (UCEC) and uterine carcinosarcoma (UCS) compared to normal tissues. In contrast, SOX11 expression was significantly downregulated in colon adenocarcinoma (COAD) and rectum adenocarcinoma (READ; Figure 1C).

3.2. Protein Expression of the SOX11 in Human Tissues

We then detected the protein level of SOX11 using human pan-cancer tissue arrays. According to the results, SOX11 was expressed in the normal stomach (n = 4; Figure 2C), pancreas (n = 4; Figure 2G) and kidney (n = 3; Figure 2K) tissues, and it was slightly expressed in the normal colon tissues (n = 4; Figure 2D). SOX11 expression was also found in the cancer tissues of the thyroid (n = 2; Figure 2A), esophagus (n = 3; Figure 2B), colon (n = 6; Figure 2D), rectum (n = 4; Figure 2E), liver (n = 5; Figure 2F), lung (n = 7; Figure 2H,I) and breast (n = 4; Figure 2J) tissues. The expression of SOX11 was higher in ESCA, LUSC and LUAD than in normal tissues. In contrast, SOX11 was more lowly expressed in KIRC than in the corresponding normal tissues. SOX11 tended to have a higher expression in COAD and BRCA, while a lower expression of SOX11 was also found in STAD. But the difference was not statistically significant due to the small sample size. The semiquantitative immunohistochemical results and statistical analysis were summarized in Table S1. The result was not consistent with the mRNA expression level of COAD, STAD, PAAD and KIRC of TCGA data. We speculated that it might be due to the small sample size or tumor heterogeneity. We also verified the SOX11 protein level in cancer and corresponding normal tissues using the HPA database (Figure S1).

3.3. Prognostic Value of SOX11 in Pan-Cancer

To further explore the prognostic value of SOX11 in pan-cancer, Kaplan-Meier analysis was used to assess the relationship between SOX11 expression level and different survival outcomes. Kaplan-Meier analysis showed that high expression of SOX11 is a risk factor for survival in certain tumors. First, high SOX11 expression was correlated with ACC (p < 0.001, Figure 3A), kidney renal papillary cell carcinoma (KIRP; p < 0.001, Figure 3B), LIHC (p < 0.001, Figure 3C), pheochromocytoma and paraganglioma (PCPG; p = 0.036, Figure 3D), sarcoma (SARC; p = 0.024, Figure 3E) and UCEC (p = 0.005; Figure 3F) in terms of overall survival. Regarding PFS, higher SOX11 expression levels in ACC (p < 0.001; Figure 3G), BRCA (p = 0.021; Figure 3H), KIRC (p = 0.016; Figure 3I), LIHC (p < 0.001; Figure 3J), PRAD (p < 0.001; Figure 3K), SARC (p < 0.05; Figure 3L) and UCEC (p < 0.05, Figure 3M) were associated with shorter PFS. In addition, patients with high levels of SOX11 expression also had significantly shortened DFS in ACC (p = 0.013; Figure 4A), KIRP (p = 0.028; Figure 4B), LIHC (p = 0.008; Figure 4C), PAAD (p = 0.009; Figure 4D) and PRAD (p < 0.001; Figure 4E). In addition, the same results were observed for DSS, especially in ACC (p < 0.001; Figure 4F), BRCA (p = 0.003; Figure 4G), KIRC (p = 0.006; Figure 4H), KIRP (p = 0.005; Figure 4I), LIHC (p < 0.001; Figure 4J) and UCEC (p < 0.001; Figure 4K).

3.4. Associations between the SOX11 Expression with Clinicopathological Features in Pan-Cancer

We compared the differences in SOX11 expression levels at different tumor stages. In ACC (Figure 5A), COAD (Figure 5B), ESCA (Figure 5C), TGCT (Figure 5D) and UVM (Figure 5E), the expression of SOX11 showed an increasing trend with increasing tumor stage. It has also been known that post-treatment tumor status was strongly associated with disease recurrence. We found that high expression of SOX11 was significantly associated with tumor status in ACC (Figure 5F), PRAD (Figure 5G), UCEC (Figure 5H) and UVM (Figure 5I).

3.5. Analysis of Genetic Alterations in the SOX11 Gene of Pan-Cancer Patients

Next, we further investigated the genomic alterations of SOX11 using the TCGA pan-cancer dataset. As shown in Figure 6A, the SOX11 gene was found to be altered in only 1.4% of the TCGA pan-cancer dataset. As for the types of genetic alterations in SOX11 in different cancers, mutations were the most frequent, particularly in UCEC, LUSC, CESC, STAD, ESCA, COAD/READ, mesothelioma (MESO), ACC, PAAD and HNSC. Gene amplifications ranked second, and they occurred in patients with UCS, LIHC, OV, BLCA, PRAD, GBM and BRCA. Deep deletions were the most common type of genetic alteration in patients with DLBC and KICH (Figure 6B). The types, numbers and sites of the SOX11 genetic alterations are displayed in Figure 6C. Notably, missense mutations were the most common type of mutation, and it was obvious that the mutated site was located in the HMG structural domain of SOX11. Next, genetic alterations in SOX11 were analyzed in TCGA-BRCA, where the SOX11 gene was altered in 9% of all breast cancer samples. The highest frequency of genetic alterations was mRNA high expression (Figure 6D). Regarding the impact of SOX11 gene alterations on survival in BRCA patients, we found that patients with the SOX11 gene-altered group had significantly shorter DSS and PFS than those with the SOX11 gene unaltered group (Figure 6E,F).

3.6. Relationship between the SOX11 Expression and EMT-Related Genes and Stemness Scores in Pan-Cancer

Next, we investigated the correlation between SOX11 expression and stemness. First, we explored the association between SOX11 expression levels and stem cell scores in pan-cancer. Correlation analysis showed that SOX11 expression levels were positively correlated with DNAss in GBM, SARC and THCA but negatively correlated with DNAss in OV, PCPG and TGCT (Figure 7A). Furthermore, SOX11 expression levels were positively correlated with RNAss in BRCA, GBM and LGG but negatively correlated with those in COAD, HNSC, KIRC, PCPG and READ (Figure 7B). In addition, the heatmap showed positive correlations between the expression of more than 15 EMT-related genes and the expression of SOX11 in BLCA, BRCA, COAD, HNSC, KICH, KIRC, LGG, LIHC, LUSC, PAAD, READ, SARC, SKCM and TGCT (Figure 7C). Figure 7D describes the correlation between SOX11 expression and 18 tumor stem cell markers. In BRCA, COAD, GBM, LGG, LIHC, LUSC, OV, SARC, SKCM and TGCT, there was a significant positive correlation between more than 10 tumor stem cell markers and the expression of SOX11.

3.7. Correlation between SOX11 Expression and MSI, TMB and MMR-Related Genes in Cancer

The expression levels of SOX11 were further investigated for correlation with TMB, MSI and MMR in pan-cancer. The results showed that SOX11 expression was significantly correlated with increased TMB in BRCA, BLCA, ACC, TGCT, PRAD, MESO and LGG and with decreased TMB in UCS, UCEC, LUAD, KIRP and HNSC (Figure 8A). Regarding MSI, the level of SOX11 was positively correlated with increased MSI in BRCA, TGCT, SARC, PRAD and OV, while they were negatively correlated in SKCM and KIRC (Figure 8B). As shown in Figure 8C, SOX11 expression was significantly positively correlated with the expression of MMR-related genes in most tumors, particularly in BRCA, GBM, LGG, LIHC, LUAD and OV.

3.8. Relevance of SOX11 Expression to the Tumor Immune Microenvironment

Currently, the predictive role of SOX11 in the tumor immune microenvironment remains unknown. Here, the correlation between SOX11 expression and the tumor immune microenvironment was assessed using the ESTIMATE method. Our results showed that SOX11 expression was positively correlated with the ESTIMATE scores in BLCA, COAD, PCPG, READ, THCA and UVM, as well as immune scores (Figure 9A,B). We also explored the relationship between SOX11 expression and immune cell infiltration in pan-cancer. The results showed that SOX11 expression correlated with the level of infiltration of all 15 immune cell types, including B cells, plasma cells, CD4+ T cells, CD8+ T cells, M0 macrophages, M1 macrophages, M2 macrophages, monocytes, NK cells, neutrophils, follicular helper T cells, γΔT cells, Treg cells, dendritic cells, and mast cells (Figure S2). We found that in COAD, HNSC, LUAD, PAAD, SKCM, THCA and THYM, the infiltration levels of CD8+ T cells were all significantly negatively correlated with the expression levels of SOX11 (Figure 9C–I).

3.9. The Biological Function of SOX11 in Pan-Cancer

The main biological processes of SOX11 in cancers were investigated by GSEA. Regarding the KEGG pathways analysis, our results demonstrated that SOX11 was positively correlated with the metabolism-related pathways in OV, such as the ascorbate and aldehyde metabolism, pentose and glucuronate interconversion and drug metabolism cytochrome P450. However, SOX11 was negatively enriched in metabolism-related pathways of KIRC, such as the citrate cycle, folate biosynthesis and steroid biosynthesis. Moreover, SOX11 positively regulated immune-related pathways in PAAD, PRAD and STAD, such as antigen presentation and the RIG-I-like receptor signaling pathway. SOX11 was also found to be positively associated with disease-related pathways, including dilated cardiomyopathy, hypertrophic cardiomyopathy and maturity-onset diabetes of the young. In addition, SOX11 was identified as a positive regulator of olfactory transduction and autophagy in HNSC, KIRC, LUSC, OV, PAAD, PRAD and STAD. We also found that SOX11 is closely associated with receptor-related pathways, including negative regulation of the Nod-like and Toll-like receptor signaling pathway in GBM, but positive regulation of these receptor-related pathways in LUSC, PAAD, PRAD and STAD. (Figure 10) The GO results of GSEA analysis of SOX11 in pan-cancer were shown in Figures S3 and S4. SOX11 was positively enriched in ACC, COAD, DLBC, ESCA, GBM, acute myeloid leukemia (LAML), LGG, LUAD, LUSC, MESO, OV, PCPG, PRAD, STAD, THYM and UCEC in gene regulatory mechanisms such as gene silencing, mRNA-mediated gene silencing, miRNA-mediated translational repression, mRNA binding and chromosome segregation regulation. In CHOL, KICH, KIRC and UVM, SOX11 was also positively enriched in a variety of immune response pathways, such as regulation of cell surface receptor signaling, regulation of immune effector processes and production of molecular mediators of immune responses. In contrast, SOX11 was negatively enriched in BLCA, CESC, KIRC, LIHC, LUAD, LUSC, PRAD, SKCM, TGCT and UCS in the regulation of cell cycle G1/S transition, epidermal cell growth, epidermal cell differentiation and epithelial cell migration.

4. Discussion

In this study, we found that SOX11 was highly expressed in the brain, colon, heart, pituitary gland and spleen tissues, while it was expressed at lower levels in other normal human tissues. The results of tissue microarray showed that SOX11 was positively expressed in the normal thyroid, esophagus, stomach, colon, rectum, liver, pancreas and kidney. Previous studies demonstrated that SOX11 was highly expressed in the central nervous system, gastrointestinal tract, lung, spleen, pancreas, kidney and gonads in normal humans [12,13,14]. SOX11 was reported to be highly expressed in breast cancer [17], mantle cell lymphoma [18], epithelial ovarian cancer [19] and hepatocellular carcinoma [20], while it was expressed at low levels in nasopharyngeal carcinoma [21], prostate cancer [22], gastric cancer (GC) [23] and bladder cancer [24]. However, we discovered that SOX11 expression was altered in 27 cancer tissues from the TCGA database compared to normal tissues. The mRNA level of SOX11 was upregulated in most of the cancer tissues except COAD and READ. In the tissue microarray, SOX11 was more highly expressed in ESCA, LUSC and LUAD than in the corresponding normal tissues, but the results were reversed in KIRC. We also observed that SOX11 tended to have a higher expression in COAD, READ, LIHC and BRCA than in the corresponding normal tissues, and the effect was reversed in STAD and PAAD. However, these differences did not reach statistical significance. Additionally, we found that SOX11 was differentially expressed in male and female breast tissues, which might be due to the differences volume and structure of male and female mammary glands. In summary, compared to corresponding normal tissues, SOX11 protein level was upregulated in ESCA, THCA, COAD, READ, LIHC, LUSC, LUAD and BRCA. In contrast, SOX11 protein level was downregulated in STAD, PAAD and KIRC.
Regarding the prognostic value of SOX11 in cancer, the available findings are controversial. SOX11 was reported to act as both an oncogenic and a tumor suppressor. For example, SOX11 was considered to be a key oncogenic factor in MCL [37]. And the high expression of SOX11 was strongly associated with poor prognostic factors of chronic lymphocytic leukemia (CLL) [38]. Regarding the mRNA level of SOX11 in DLBCL, a previous study also exhibited a low transcriptional level of SOX11 in patients with DLBCL, which was consistent with our findings [39]. In breast cancer, high SOX11 expression levels were also significantly associated with distant metastasis and poor prognosis [40]. Additionally, SOX11 could promote brain metastasis in triple-negative breast cancer (TNBC) [41]. In hepatic cell carcinoma (HCC), higher mRNA transcript levels of SOX11 were associated with shorter OS and PFS [42]. However, it was reported that the upregulation of SOX11 expression might be a good prognostic factor for patients with MCL [18]. Additionally, SOX11 was found to be an independent prognostic factor for improving survival in gastric cancer [43]. Studies revealed that the overexpression of SOX11 inhibited the invasion of COAD [44], and the upregulation of SOX11 also hindered the invasion and proliferation of LUAD cells [45]. In particular, high nuclear expression of SOX11 was found to be associated with longer OS in breast cancer patients, which meant that it was an independent predictor of survival [46]. In this study, our Kaplan–Meier survival analysis showed that high expression of SOX11 was significantly correlated with poor survival in patients with ACC, KIRP, LIHC, PCPG, SARC, UCEC, KIRC, PRAD, PAAD and BRCA, including OS, PFS, DFS and DSS. Our study suggested that SOX11 was associated with poor survival in both HCC and BRCA, which contradicted some previous studies.
We next explored the relationship of SOX11 expression with the clinicopathological parameters of patients. It was previously reported that high SOX11 expression was positively correlated with breast cancer tumor size and early tumor grade and negatively correlated with lymph node metastasis in breast cancer [46]. Clinical studies also showed that SOX11-positive MCL patients with lymph node involvement had a poorer prognosis [47]. In addition, high mRNA levels of SOX11 in HCC were closely associated with the high grade of the tumor [42]. In our study, SOX11 expression levels in ACC, COAD, ESCA, TGCT and UVM showed an increasing trend with increasing tumor stage, but the trend was more pronounced mainly in tumor stages I-III which might be due to the small sample size of stage IV patients. In addition, we found that high expression of SOX11 was significantly associated with tumor status in ACC, PRAD, UCEC and UVM, which indicated that SOX11 might have the potential to reflect tumor progression.
Regarding genetic alterations of SOX11 in pan-cancer, our data found that mutations were the most common type of genetic alteration of SOX11, followed by amplifications. SOX11 mutations were reported to occur frequently in the hotspot(D233 del/2_D233 del) in esophageal, gastric and lung cancers, while amplification was the major form of genetic alteration in neuroendocrine prostate cancer (NEPC), OV, PRAD, BRCA and UCEC [48]. A study explored the genetic alterations of the SOX family in patients with HCC and found that all genes in the SOX family had some genetic alterations, including missense mutations, truncating mutations, amplifications, deep deletions and high mRNA [42]. It was important to note that SOX11 amplification or mutation was uncommon in primary cancers [49], but SOX11 amplification and upregulation of expression were found in metastatic brain cancers [50], which was consistent with the results of our study. We found that SOX11 mutations were most seen in esophageal, gastric and lung cancers, while SOX11 amplification was most commonly seen in liver cancer. However, the expression level and genetic alterations of SOX11 in metastatic cancers remain unknown. In addition, our study found for the first time that SOX11 amplification was the most common form of gene alteration in BLCA and GBM, and the deep deletion of SOX11 gene was most common in DLBC and KICH. Our study also identified missense mutations located in the high-mobility-group (HMG) domain of SOX11, which was also consistent with previous reports [51]. What’s more, patients in the SOX11 altered group had shorter DSS and PFS than patients in the SOX11 unaltered group, suggesting that SOX11 gene alterations, particularly high mRNA levels, were risk factors for prognosis in breast cancer. However, the mechanisms were not clear, which might need to be further explored in future experimental and clinical studies.
Cancer stem cells (CSCs), a subpopulation of cancer cells, have similar characteristics to normal stem/progenitor cells, such as the ability to self-renew and differentiate to drive tumor growth [52]. Our study found that SOX11 expression was highly correlated with stem cell markers as well as EMT-related genes. A previous study confirmed that SOX11 was identified as a characteristic gene of mesenchymal stem cells (MSCs) and a potential biomarker for early progenitor human MSCs [53]. Microarray analysis showed that SOX11 mRNA gradually decreased during the expansion of bone marrow MSCs, suggesting that SOX11 could be used as a biomarker to distinguish early progenitor cells from mature bone marrow MSCs [54]. It was found that SOX11 was a better biomarker of breast cancer stem cells that could predict cancer recurrence. Furthermore, SOX11 expression was directly associated with breast cancer stem cell populations and correlated with overexpression of ALDH1 [48]. Bhattaram et al. suggested that SOXC proteins might control the fate and behavior of stem/progenitor cells in many lineages through a mechanism distinct from other SOX proteins [55]. EMT is a common process in tumorigenesis and has long been considered to be an important embryonic process. SOX11 was upregulated in TGF-β and EGF-induced EMT in renal tubular epithelial cells, suggesting a possible involvement of SOX11 in EMT [56]. Another study showed that SOX11 could activate SLUG expression in endocrine-resistant breast cancer cell lines by binding to its promoter, thereby promoting EMT [57].
Evidence suggests that MSI and TMB could serve as potential indicators of response to immunotherapy [58]. Notably, immunotherapies have also shown efficacy for CRC patients with mismatch-repair-deficient and microsatellite instability-high (dMMR-MSI-H) [59]. It has been reported that SOX11 hypermethylation is closely associated with MSI in endometrial cancer [60]. Our results showed that SOX11 expression positively correlated with elevated MSI in BRCA, TGCT, SARC, PRAD and OV, as well as with elevated TMB in BRCA, BLCA, ACC, TGCT, PRAD, MESO and LGG. The results above indicated that SOX11 might also serve as a novel and effective biomarker for predicting the efficacy of immunotherapy. The TME is defined as the cellular environment in which a tumor is located, grows and expands. Tumor cells release extracellular factors such as vascular endothelial growth factor, molecules that promote tumor angiogenesis or induce peripheral immune tolerance [61]. Balsas et al. showed that SOX11 regulated MCL homing and invasion by directly regulating CXCR4 and FAK expression [62]. The correlation between SOX11 expression and immune cell content might depend on tumor cell type according to the ESTIMATE algorithm. Studies found that intra-tumoral infiltrations of T cells were significantly reduced in SOX11+ MCL [63]. Further analysis revealed that SOX11 expression correlated significantly with the level of infiltration of various immune cells, particularly in BRCA, CESC, COAD, HNSC and KIRC. In COAD, HNSC, LUAD, PAAD, SKCM, THCA and THYM, CD8+ T cell infiltration levels were all significantly negatively correlated with SOX11 expression levels, suggesting that SOX11 might be associated with immune escape. At present, less research has been done regarding the role of SOX11 in immune regulation. The relationship between SOX11 expression and immune infiltration requires further investigation in vitro and in vivo.
Our GSEA analysis showed that SOX11 expression was closely associated with metabolism-related pathways, immune-related pathways, disease-related pathways and receptor-related pathways. GO analysis showed that SOX11 expression was positively enriched in gene regulatory mechanisms as well as multiple immune response pathways, while SOX11 expression was negatively enriched in the regulation of cell cycle G1/S transition, epidermal cell growth, epidermal cell differentiation and epithelial migration. SOX11 has been reported to affect apoptosis-associated cell survival pathways, TEAD2 transcriptional activity, mitosis and immune-inflammatory responses [15,48,64]. It has also been shown that SOX11 may be associated with specific key pathways related to certain developmental processes, including the WNT signaling pathway and the TCF/β-linked protein complex in hepatocellular carcinoma [65]. In addition, we found that SOX11 could activate the bone morphogenetic protein (BMP)/Smad signaling pathway in mesenchymal stem cells (MSCs) and could transcriptionally activate runt-related transcription factor 2 (Runx2) and CXC chemokine receptor-4 (CXCR4) expression [53]. Our study also identified that one signaling pathway could be significantly enriched in multiple tumor types, such as gene silencing, miRNA-mediated translational repression, mRNA binding and chromosome segregation regulation. Thus, we suggested that SOX11-mediated pathways in different cancers were not specific.
The significance of this study is to reveal the prognostic value of SOX11 in pan-cancer, which not only further supports previous findings but also contributes to our understanding of the multifaceted role of SOX11 in tumor progression. As our study conducted a comprehensive bioinformatics analysis that relies on multiple databases, there were inevitably some limitations of our analyses. First, further experimental validation is required in future studies to confirm these results. Second, most of our analyses focused on SOX11 mRNA expression. It is worth mentioning that analysis based on SOX11 protein levels would enhance the credibility of the results. Third, only relevant analyses were performed in this study, and the molecular mechanisms of SOX11 in tumor stemness and immune infiltration require further investigation.

5. Conclusions

In summary, this study systematically explored the characteristics of SOX11 in terms of expression patterns, survival prognosis, gene mutations, stemness, TMB, MSI, immune infiltration and related signaling pathways. SOX11 may be a potential biomarker in cancer, as it exhibits aberrantly high expression in a variety of cancers and predicts poor prognosis in cancer patients. In different cancers, a large number of mutations, amplifications and high mRNA levels were observed in SOX11. In addition, aberrant SOX11 expression was associated with stem cell scoring, EMT-related genes, MSI, TMB and the tumor immune microenvironment in different cancer types. Finally, our work also suggests several future directions for future prospective studies that focus on SOX11 in cancer.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers14246103/s1, Figure S1: Protein expression level of SOX11 in cancer and corresponding normal tissues from the HPA da-tabase of BRCA, COAD, LIHC, LUSC, THCA, STAD, PAAD, KIRC; Figure S2: (A) Correlation between CD4+ T cell infiltration and SOX11 expression in BRCA. (B) Correlation between CD8+ T cell infiltration and SOX11 expression in CESC. (C) Correlation between mac-rophage M0 infiltration and SOX11 expression in COAD. (D) Correlation between macrophage M2 cell infiltration and SOX11 expression in HNSC. (E) Correlation between gamma delta T cell infil-tration and SOX11 expression in KIRC. (F) Correlation between macrophage M1 cell infiltration and SOX11 expression in KIRP. (G) Correlation between neutrophil infiltration and SOX11 expression in LIHC. (H) Correlation between monocyte cell infiltration and SOX11 expression in PAAD. (I) Correlation between mast cell infiltration and SOX11 expression in SARC. (J) Correlation between plasma cell infiltration and SOX11 expression in SKCM.. (K) Correlation between T follicular helper cell infiltration and SOX11 expression in SKCM. (L) Correlation between dendritic cell infiltration and SOX11 expression in STAD. (M) Correlation between B cell infiltration and SOX11 expression in TGCT. (N) Correlation between NK cell infiltration and SOX11 expression in THCA. (O) Correla-tion between Treg cell infiltration and SOX11 expression in THCA; Figure S3: The Gene Set Enrichment Analysis (GSEA) in Gene Ontology (GO) signature of THCA, ESCA, STAD, BRCA, READ and COAD; Figure S4: The Gene Set Enrichment Analysis (GSEA) in Gene Ontology (GO) signature of LIHC, PAAD, LUAD, LUSC, KIRC and CHOL; Table S1: The protein expression of SOX11 in pan-cancer by tissue microarray.

Author Contributions

Conceptualization: X.H. and Q.S. Methodology: S.P. and J.D. (Jun Du) Software and Validation: Q.S. and H.J. Writing—Original Draft Preparation: Q.S. Writing—Review & Editing: Q.S., J.D. (Jie Dong) and J.Z. Supervision: X.H. and J.Z. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

All datasets used in this study have been previously published. The study was conducted in accordance with the Declaration of Helsinki, and ap-proved by the Ethics Committee of Shanghai Outdo Biotech Co., Ltd. (protocol code SHYJS-CP-1901007 and date of approval: 2 January 2019).

Informed Consent Statement

Patient consent was waived due to the use of a commercial tissue microarray and the retrospective nature of the study.

Data Availability Statement

All the data are available from the TCGA database and cBioPortal database.

Acknowledgments

We are thankful for all research participants and clinicians involved in this research. We acknowledged the TCGA database and cBioPortal database for providing their platforms and contributors for uploading their meaningful datasets.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

ACC: Adrenocortical Carcinoma; BLCA, Bladder Urothelial Carcinoma; BRCA, Breast Invasive Carcinoma; CESC, Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma; CHOL, Cholangiocarcinoma; COAD, Colon Adenocarcinoma; DFS, Disease-Free Survival; DLBC, Lymphoid Neoplasm Diffuse Large B-cell Lymphoma; DNAss, DNA stemness score; DSS, Disease-Specific Survival; ESCA, Esophageal Carcinoma; GBM, Glioblastoma Multiforme; GO, Gene Ontology; GSEA, Gene Set Enrichment Analysis; GTEX, Genotype Tissue-Expression; HNSC, Head and Neck Squamous Cell Carcinoma; HR, Hazard Ratio; KEGG, Kyoto Encyclopedia of Genes and Genomes; KICH, Kidney Chromophobe; KIRC, Kidney Renal Clear Cell Carcinoma; KIRP, Kidney Renal Papillary Cell Carcinoma; LGG, Brain Lower Grade Glioma; LIHC, Liver Hepatocellular Carcinoma; LUAD, Lung Adenocarcinoma; LUSC, Lung Squamous Cell Carcinoma; MESO, Mesothelioma; MMR, Mismatch Repair; MSI, Microsatellite Instability; OS, Overall Survival; OV, Ovarian Serous Cystadenocarcinoma; PAAD, Pancreatic Adenocarcinoma; PCPG, Pheochromocytoma and Paraganglioma; PFS, Progression-Free Survival; PRAD, prostate adenocarcinoma; READ, Rectum Adenocarcinoma; RNAss, RNA stemness score; SARC, Sarcoma; SKCM, Skin Cutaneous Melanoma; SOX11, SRY-box Transcription Factor 11; STAD, Stomach Adenocarcinoma; TCGA, The Cancer Genome Atlas; TGCT, Testicular Germ Cell Tumors; THCA, Thyroid Carcinoma; THYM, Thymoma; TMB, Tumor Mutation Burden; UCEC, Uterine Corpus Endometrial Carcinoma; UCS, Uterine Carcinosarcoma.

References

  1. Xia, C.; Dong, X.; Li, H.; Cao, M.; Sun, D.; He, S.; Yang, F.; Yan, X.; Zhang, S.; Li, N.; et al. Cancer statistics in China and United States, 2022: Profiles, trends, and determinants. Chin. Med. J. 2022, 135, 584–590. [Google Scholar] [CrossRef] [PubMed]
  2. Grimm, D.; Bauer, J.; Wise, P.; Kruger, M.; Simonsen, U.; Wehland, M.; Infanger, M.; Corydon, T.J. The role of SOX family members in solid tumours and metastasis. Semin. Cancer Biol. 2020, 67, 122–153. [Google Scholar] [CrossRef] [PubMed]
  3. Lefebvre, V.; Dumitriu, B.; Penzo-Méndez, A.; Han, Y.; Pallavi, B. Control of cell fate and differentiation by Sry-related high-mobility-group box (SOX) transcription factors. Int. J. Biochem. Cell Biol. 2007, 39, 2195–2214. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Cizelsky, W.; Hempel, A.; Metzig, M.; Tao, S.; Hollemann, T.; Kühl, M.; Kühl, S.J. SOX4 and SOX11 function during Xenopus laevis eye development. PLoS ONE 2013, 8, e69372. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Bowles, J.; Schepers, G.; Koopman, P. Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev. Biol. 2000, 227, 239–255. [Google Scholar] [CrossRef] [Green Version]
  6. Hoser, M.; Potzner, M.R.; Koch, J.M.; Bösl, M.R.; Wegner, M.; Sock, E. SOX12 deletion in the mouse reveals nonreciprocal redundancy with the related SOX4 and SOX11 transcription factors. Mol. Cell. Biol. 2008, 28, 4675–4687. [Google Scholar] [CrossRef] [Green Version]
  7. Tsang, S.M.; Oliemuller, E.; Howard, B.A. Regulatory roles for SOX11 in development, stem cells and cancer. Semin. Cancer Biol. 2020, 67, 3–11. [Google Scholar] [CrossRef]
  8. Jiang, Y.; Ding, Q.; Xie, X.; Libby, R.T.; Lefebvre, V.; Gan, L. Transcription factors SOX4 and SOX11 function redundantly to regulate the development of mouse retinal ganglion cells. J. Biol. Chem. 2013, 288, 18429–18438. [Google Scholar] [CrossRef] [Green Version]
  9. Kamachi, Y.; Kondoh, H. SOX proteins: Regulators of cell fate specification and differentiation. Development 2013, 140, 4129–4144. [Google Scholar] [CrossRef] [Green Version]
  10. Wasik, A.M.; Lord, M.; Wang, X.; Zong, F.; Andersson, P.; Kimby, E.; Christensson, B.; Karimi, M.; Sander, B. SOXC transcription factors in mantle cell lymphoma: The role of promoter methylation in SOX11 expression. Sci. Rep. 2013, 3, 1400. [Google Scholar] [CrossRef]
  11. Vegliante, M.C.; Royo, C.; Palomero, J.; Salaverria, I.; Balint, B.; Martín-Guerrero, I.; Agirre, X.; Lujambio, A.; Richter, J.; Xargay-Torrent, S.; et al. Epigenetic activation of SOX11 in lymphoid neoplasms by histone modifications. PLoS ONE 2011, 6, e21382. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Potzner, M.R.; Tsarovina, K.; Binder, E.; Penzo-Méndez, A.; Lefebvre, V.; Rohrer, H.; Wegner, M.; Sock, E. Sequential requirement of SOX4 and SOX11 during development of the sympathetic nervous system. Development 2010, 137, 775–784. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Sock, E.; Rettig, S.D.; Enderich, J.; Bösl, M.R.; Tamm, E.R.; Wegner, M. Gene targeting reveals a widespread role for the high-mobility-group transcription factor SOX11 in tissue remodeling. Mol. Cell. Biol. 2004, 24, 6635–6644. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Pamnani, M.; Sinha, P.; Nara, S.; Sachan, M. Study of promoter DNA methylation of SOX11 and its correlation with tissue-specific expression in the laboratory mouse. Gene 2014, 552, 133–139. [Google Scholar] [CrossRef]
  15. Yang, Z.; Jiang, S.; Lu, C.; Ji, T.; Yang, W.; Li, T.; Lv, J.; Hu, W.; Yang, Y.; Jin, Z. SOX11: Friend or foe in tumor prevention and carcinogenesis? Ther. Adv. Med. Oncol. 2019, 11, 1758835919853449. [Google Scholar] [CrossRef] [Green Version]
  16. Sun, H.; Zhou, H.; Zhang, Y.; Chen, J.; Han, X.; Huang, D.; Ren, X.; Jia, Y.; Fan, Q.; Tian, W.; et al. Aberrant methylation of FAT4 and SOX11 in peripheral blood leukocytes and their association with gastric cancer risk. J. Cancer 2018, 9, 2275–2283. [Google Scholar] [CrossRef] [Green Version]
  17. Wang, F.W.; Ao, X.; Fu, S.M. Expression of SOX11 and HER2 and their association with recurrent breast cancer. Transl. Cancer Res. 2019, 8, 248–254. [Google Scholar] [CrossRef]
  18. He, J.X.; Xi, Y.F.; Su, L.P.; Gao, N.; Xu, E.W.; Xie, L.W.; Wang, L.Y.; Zheng, Y.P.; Han, W.E.; Chang, J.; et al. Association of SOX11 gene expression withclinical features and prognosis of mantle cell lymphoma. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 2556–2563. [Google Scholar] [CrossRef]
  19. Brennan, D.J.; Ek, S.; Doyle, E.; Drew, T.; Foley, M.; Flannelly, G.; O’Connor, D.P.; Gallagher, W.M.; Kilpinen, S.; Kallioniemi, O.P.; et al. The transcription factor SOX11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer. Eur. J. Cancer 2009, 45, 1510–1517. [Google Scholar] [CrossRef]
  20. Teng, Y.; Fan, Y.C.; Mu, N.N.; Zhao, J.; Sun, F.K.; Wang, K. Serum SOX11 promoter methylation is a novel biomarker for the diagnosis of Hepatitis B virus-related hepatocellular carcinoma. Neoplasma 2016, 63, 419–426. [Google Scholar] [CrossRef]
  21. Zhang, S.; Li, S.; Gao, J.L. Promoter methylation status of the tumor suppressor gene SOX11 is associated with cell growth and invasion in nasopharyngeal carcinoma. Cancer Cell Int. 2013, 13, 109. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Yao, Z.; Sun, B.; Hong, Q.; Yan, J.; Mu, D.; Li, J.; Sheng, H.; Guo, H. The role of tumor suppressor gene SOX11 in prostate cancer. Tumour Biol. 2015, 36, 6133–6138. [Google Scholar] [CrossRef] [PubMed]
  23. Xu, X.; Chang, X.; Li, Z.; Wang, J.; Deng, P.; Zhu, X.; Liu, J.; Zhang, C.; Chen, S.; Dai, D. Aberrant SOX11 promoter methylation is associated with poor prognosis in gastric cancer. Cell. Oncol. 2015, 38, 183–194. [Google Scholar] [CrossRef]
  24. Chung, W.; Bondaruk, J.; Jelinek, J.; Lotan, Y.; Liang, S.; Czerniak, B.; Issa, J.P. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol. Biomark. Prev. 2011, 20, 1483–1491. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Beekman, R.; Amador, V.; Campo, E. SOX11, a key oncogenic factor in mantle cell lymphoma. Curr. Opin. Hematol. 2018, 25, 299–306. [Google Scholar] [CrossRef]
  26. Zvelebil, M.; Oliemuller, E.; Gao, Q.; Wansbury, O.; Mackay, A.; Kendrick, H.; Smalley, M.J.; Reis-Filho, J.S.; Howard, B.A. Embryonic mammary signature subsets are activated in Brca1−/− and basal-like breast cancers. Breast Cancer Res. 2013, 15, R25. [Google Scholar] [CrossRef] [Green Version]
  27. Shepherd, J.H.; Uray, I.P.; Mazumdar, A.; Tsimelzon, A.; Savage, M.; Hilsenbeck, S.G.; Brown, P.H. The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. Oncotarget 2016, 7, 13106–13121. [Google Scholar] [CrossRef]
  28. Oliemuller, E.; Kogata, N.; Bland, P.; Kriplani, D.; Daley, F.; Haider, S.; Shah, V.; Sawyer, E.J.; Howard, B.A. SOX11 promotes invasive growth and ductal carcinoma in situ progression. J. Pathol. 2017, 243, 193–207. [Google Scholar] [CrossRef] [Green Version]
  29. Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 2013, 6, pl1. [Google Scholar] [CrossRef] [Green Version]
  30. Malta, T.M.; Sokolov, A.; Gentles, A.J.; Burzykowski, T.; Poisson, L.; Weinstein, J.N.; Kamińska, B.; Huelsken, J.; Omberg, L.; Gevaert, O.; et al. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 2018, 173, 338–354.e315. [Google Scholar] [CrossRef]
  31. Cohen, R.; Hain, E.; Buhard, O.; Guilloux, A.; Bardier, A.; Kaci, R.; Bertheau, P.; Renaud, F.; Bibeau, F.; Fléjou, J.F.; et al. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer with Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. JAMA Oncol. 2019, 5, 551–555. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Passaro, A.; Stenzinger, A.; Peters, S. Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence. Cancer Cell 2020, 38, 624–625. [Google Scholar] [CrossRef] [PubMed]
  33. Bonneville, R.; Krook, M.A.; Kautto, E.A.; Miya, J.; Wing, M.R.; Chen, H.Z.; Reeser, J.W.; Yu, L.; Roychowdhury, S. Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis. Oncol. 2017, 2017, 1–15. [Google Scholar] [CrossRef]
  34. Davies, H.; Glodzik, D.; Morganella, S.; Yates, L.R.; Staaf, J.; Zou, X.; Ramakrishna, M.; Martin, S.; Boyault, S.; Sieuwerts, A.M.; et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med. 2017, 23, 517–525. [Google Scholar] [CrossRef]
  35. Yoshihara, K.; Shahmoradgoli, M.; Martínez, E.; Vegesna, R.; Kim, H.; Torres-Garcia, W.; Treviño, V.; Shen, H.; Laird, P.W.; Levine, D.A.; et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 2013, 4, 2612. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Newman, A.M.; Liu, C.L.; Green, M.R.; Gentles, A.J.; Feng, W.; Xu, Y.; Hoang, C.D.; Diehn, M.; Alizadeh, A.A. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 2015, 12, 453–457. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Mozos, A.; Royo, C.; Hartmann, E.; De Jong, D.; Baró, C.; Valera, A.; Fu, K.; Weisenburger, D.D.; Delabie, J.; Chuang, S.S.; et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009, 94, 1555–1562. [Google Scholar] [CrossRef] [Green Version]
  38. Balta, E.A.; Wittmann, M.T.; Jung, M.; Sock, E.; Haeberle, B.M.; Heim, B.; von Zweydorf, F.; Heppt, J.; von Wittgenstein, J.; Gloeckner, C.J.; et al. Phosphorylation Modulates the Subcellular Localization of SOX11. Front. Mol. Neurosci. 2018, 11, 211. [Google Scholar] [CrossRef]
  39. Cao, X.; Fan, L.; Fang, C.; Zhu, D.X.; Dong, H.J.; Wang, D.M.; Wang, Y.H.; Xu, W.; Li, J.Y. The expression of SOX11, cyclin D1, cyclin D2, and cyclin D3 in B-cell lymphocytic proliferative diseases. Med. Oncol. 2012, 29, 1190–1196. [Google Scholar] [CrossRef]
  40. Oliemuller, E.; Newman, R.; Tsang, S.M.; Foo, S.; Muirhead, G.; Noor, F.; Haider, S.; Aurrekoetxea-Rodríguez, I.; Vivanco, M.D.; Howard, B.A. SOX11 promotes epithelial/mesenchymal hybrid state and alters tropism of invasive breast cancer cells. eLife 2020, 9, e58374. [Google Scholar] [CrossRef]
  41. Pan, J.K.; Lin, C.H.; Kuo, Y.L.; Ger, L.P.; Cheng, H.C.; Yao, Y.C.; Hsiao, M.; Lu, P.J. MiR-211 determines brain metastasis specificity through SOX11/NGN2 axis in triple-negative breast cancer. Oncogene 2021, 40, 1737–1751. [Google Scholar] [CrossRef] [PubMed]
  42. Qin, S.; Liu, G.; Jin, H.; Chen, X.; He, J.; Xiao, J.; Qin, Y.; Mao, Y.; Zhao, L. The Dysregulation of SOX Family Correlates with DNA Methylation and Immune Microenvironment Characteristics to Predict Prognosis in Hepatocellular Carcinoma. Dis. Markers 2022, 2022, 2676114. [Google Scholar] [CrossRef] [PubMed]
  43. Qu, Y.; Zhou, C.; Zhang, J.; Cai, Q.; Li, J.; Du, T.; Zhu, Z.; Cui, X.; Liu, B. The metastasis suppressor SOX11 is an independent prognostic factor for improved survival in gastric cancer. Int. J. Oncol. 2014, 44, 1512–1520. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Wu, H.; Dai, Y.; Zhang, D.; Zhang, X.; He, Z.; Xie, X.; Cai, C. LINC00961 inhibits the migration and invasion of colon cancer cells by sponging miR-223-3p and targeting SOX11. Cancer Med. 2020, 9, 2514–2523. [Google Scholar] [CrossRef] [PubMed]
  45. Ma, Z.; Chen, G.; Chen, Y.; Guo, Z.; Chai, H.; Tang, Y.; Zheng, L.; Wei, K.; Pan, C.; Ma, Z.; et al. MiR-937-3p promotes metastasis and angiogenesis and is activated by MYC in lung adenocarcinoma. Cancer Cell Int. 2022, 22, 31. [Google Scholar] [CrossRef] [PubMed]
  46. Liu, D.T.; Peng, Z.; Han, J.Y.; Lin, F.Z.; Bu, X.M.; Xu, Q.X. Clinical and prognostic significance of SOX11 in breast cancer. Asian Pac. J. Cancer Prev. 2014, 15, 5483–5486. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Xu, J.; Wang, L.; Li, J.; Saksena, A.; Wang, S.A.; Shen, J.; Hu, Z.; Lin, P.; Tang, G.; Yin, C.C.; et al. SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients. Am. J. Surg. Pathol. 2019, 43, 710–716. [Google Scholar] [CrossRef]
  48. Seok, J.; Gil, M.; Dayem, A.A.; Saha, S.K.; Cho, S.G. Multi-Omics Analysis of SOX4, SOX11, and SOX12 Expression and the Associated Pathways in Human Cancers. J. Pers. Med. 2021, 11, 823. [Google Scholar] [CrossRef]
  49. Weinstein, J.N.; Collisson, E.A.; Mills, G.B.; Shaw, K.R.; Ozenberger, B.A.; Ellrott, K.; Shmulevich, I.; Sander, C.; Stuart, J.M. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 2013, 45, 1113–1120. [Google Scholar] [CrossRef]
  50. Saunus, J.M.; McCart Reed, A.E.; Lim, Z.L.; Lakhani, S.R. Breast Cancer Brain Metastases: Clonal Evolution in Clinical Context. Int. J. Mol. Sci. 2017, 18, 152. [Google Scholar] [CrossRef]
  51. Zawerton, A.; Yao, B.; Yeager, J.P.; Pippucci, T.; Haseeb, A.; Smith, J.D.; Wischmann, L.; Kühl, S.J.; Dean, J.C.S.; Pilz, D.T.; et al. De Novo SOX4 Variants Cause a Neurodevelopmental Disease Associated with Mild Dysmorphism. Am. J. Hum. Genet. 2019, 104, 246–259. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Walcher, L.; Kistenmacher, A.K.; Suo, H.; Kitte, R.; Dluczek, S.; Strauß, A.; Blaudszun, A.R.; Yevsa, T.; Fricke, S.; Kossatz-Boehlert, U. Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. Front. Immunol. 2020, 11, 1280. [Google Scholar] [CrossRef] [PubMed]
  53. Xu, L.; Huang, S.; Hou, Y.; Liu, Y.; Ni, M.; Meng, F.; Wang, K.; Rui, Y.; Jiang, X.; Li, G. SOX11-modified mesenchymal stem cells (MSCs) accelerate bone fracture healing: SOX11 regulates differentiation and migration of MSCs. FASEB J. 2015, 29, 1143–1152. [Google Scholar] [CrossRef] [Green Version]
  54. Larson, B.L.; Ylostalo, J.; Lee, R.H.; Gregory, C.; Prockop, D.J. SOX11 is expressed in early progenitor human multipotent stromal cells and decreases with extensive expansion of the cells. Tissue Eng. Part A 2010, 16, 3385–3394. [Google Scholar] [CrossRef] [Green Version]
  55. Bhattaram, P.; Muschler, G.; Wixler, V.; Lefebvre, V. Inflammatory Cytokines Stabilize SOXC Transcription Factors to Mediate the Transformation of Fibroblast-Like Synoviocytes in Arthritic Disease. Arthritis Rheumatol. 2018, 70, 371–382. [Google Scholar] [CrossRef] [Green Version]
  56. Venkov, C.; Plieth, D.; Ni, T.; Karmaker, A.; Bian, A.; George, A.L., Jr.; Neilson, E.G. Transcriptional networks in epithelial-mesenchymal transition. PLoS ONE 2011, 6, e25354. [Google Scholar] [CrossRef] [Green Version]
  57. Xiao, Y.; Xie, Q.; Qin, Q.; Liang, Y.; Lin, H.; Zeng, D. Upregulation of SOX11 enhances tamoxifen resistance and promotes epithelial-to-mesenchymal transition via slug in MCF-7 breast cancer cells. J. Cell. Physiol. 2020, 235, 7295–7308. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  58. Luchini, C.; Bibeau, F.; Ligtenberg, M.J.L.; Singh, N.; Nottegar, A.; Bosse, T.; Miller, R.; Riaz, N.; Douillard, J.Y.; Andre, F.; et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: A systematic review-based approach. Ann. Oncol. 2019, 30, 1232–1243. [Google Scholar] [CrossRef] [Green Version]
  59. Ganesh, K.; Stadler, Z.K.; Cercek, A.; Mendelsohn, R.B.; Shia, J.; Segal, N.H.; Diaz, L.A., Jr. Immunotherapy in colorectal cancer: Rationale, challenges and potential. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 361–375. [Google Scholar] [CrossRef]
  60. Shan, T.; Uyar, D.S.; Wang, L.-S.; Mutch, D.G.; Huang, T.H.M.; Rader, J.S.; Sheng, X.; Huang, Y.-W. SOX11 hypermethylation as a tumor biomarker in endometrial cancer. Biochimie 2019, 162, 8–14. [Google Scholar] [CrossRef]
  61. Korneev, K.V.; Atretkhany, K.N.; Drutskaya, M.S.; Grivennikov, S.I.; Kuprash, D.V.; Nedospasov, S.A. TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis. Cytokine 2017, 89, 127–135. [Google Scholar] [CrossRef] [PubMed]
  62. Balsas, P.; Palomero, J.; Eguileor, Á.; Rodríguez, M.L.; Vegliante, M.C.; Planas-Rigol, E.; Sureda-Gómez, M.; Cid, M.C.; Campo, E.; Amador, V. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. Blood 2017, 130, 501–513. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Balsas, P.; Veloza, L.; Clot, G.; Sureda-Gómez, M.; Rodríguez, M.L.; Masaoutis, C.; Frigola, G.; Navarro, A.; Beà, S.; Nadeu, F.; et al. SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma. Blood 2021, 138, 2202–2215. [Google Scholar] [CrossRef] [PubMed]
  64. Su, D.; Gao, Q.; Guan, L.; Sun, P.; Li, Q.; Shi, C.; Ma, X. Downregulation of SOX11 in fetal heart tissue, under hyperglycemic environment, mediates cardiomyocytes apoptosis. J. Biochem. Mol. Toxicol. 2021, 35, e22629. [Google Scholar] [CrossRef] [PubMed]
  65. Liu, Z.; Zhong, Y.; Chen, Y.J.; Chen, H. SOX11 regulates apoptosis and cell cycle in hepatocellular carcinoma via Wnt/β-catenin signaling pathway. Biotechnol. Appl. Biochem. 2019, 66, 240–246. [Google Scholar] [CrossRef] [PubMed]
Cancers 14 06103 g001 550
Figure 1. Expression analysis of SOX11. (A) The SOX11 expression in normal tissues from Genotype Tissue-Expression (GTEX) data. (B) The SOX11 expression abundances of various tissues in males and females. ***, p < 0.001. (C) Differential SOX11 mRNA expression between 33 TCGA cancers and GTEX normal tissues. The red color column represents the cancer samples, and the blue color column represents the normal samples. ns, p ≥ 0.05; **, p < 0.01; and ***, p < 0.001.
Figure 1. Expression analysis of SOX11. (A) The SOX11 expression in normal tissues from Genotype Tissue-Expression (GTEX) data. (B) The SOX11 expression abundances of various tissues in males and females. ***, p < 0.001. (C) Differential SOX11 mRNA expression between 33 TCGA cancers and GTEX normal tissues. The red color column represents the cancer samples, and the blue color column represents the normal samples. ns, p ≥ 0.05; **, p < 0.01; and ***, p < 0.001.
Cancers 14 06103 g001
Cancers 14 06103 g002 550
Figure 2. Protein expression level of SOX11 in human multiple cancer tissues and normal tissues of THCA (A), ESCA (B), STAD (C), COAD (D), READ (E), LIHC (F), PAAD (G), LUSC (H), LUAD (I), BRCA (J) and KIRC (K). Representative images of SOX11 expression in pan-cancer tissues are shown. Original magnification, ×40 and ×100, Scale bar: black, 200 μm; red, 100 μm.
Figure 2. Protein expression level of SOX11 in human multiple cancer tissues and normal tissues of THCA (A), ESCA (B), STAD (C), COAD (D), READ (E), LIHC (F), PAAD (G), LUSC (H), LUAD (I), BRCA (J) and KIRC (K). Representative images of SOX11 expression in pan-cancer tissues are shown. Original magnification, ×40 and ×100, Scale bar: black, 200 μm; red, 100 μm.
Cancers 14 06103 g002
Cancers 14 06103 g003 550
Figure 3. The Kaplan–Meier analysis of the correlations between the SOX11 expression and OS and PFS. (A–F) The Kaplan–Meier analysis of the correlations between the SOX11 expression and OS. (G–M) The Kaplan–Meier survival analysis shows the impact of SOX11 expression on PFS. The red line indicates a high SOX11 expression group, and the blue line indicates a low SOX11 expression group.
Figure 3. The Kaplan–Meier analysis of the correlations between the SOX11 expression and OS and PFS. (A–F) The Kaplan–Meier analysis of the correlations between the SOX11 expression and OS. (G–M) The Kaplan–Meier survival analysis shows the impact of SOX11 expression on PFS. The red line indicates a high SOX11 expression group, and the blue line indicates a low SOX11 expression group.
Cancers 14 06103 g003
Cancers 14 06103 g004 550
Figure 4. The Kaplan–Meier analysis of the correlations between the SOX11 expression and DFS and DSS. (A–E) The Kaplan–Meier survival analysis shows the impact of SOX11 expression on DFS. (F–K) The Kaplan–Meier survival analysis shows the impact of SOX11 expression on DSS. The red line indicates a high SOX11 expression group, and the blue line indicates a low SOX11 expression group.
Figure 4. The Kaplan–Meier analysis of the correlations between the SOX11 expression and DFS and DSS. (A–E) The Kaplan–Meier survival analysis shows the impact of SOX11 expression on DFS. (F–K) The Kaplan–Meier survival analysis shows the impact of SOX11 expression on DSS. The red line indicates a high SOX11 expression group, and the blue line indicates a low SOX11 expression group.
Cancers 14 06103 g004
Cancers 14 06103 g005 550
Figure 5. Correlation between SOX11 expression and Clinicopathological Phenotype. (A–E) Correlation between SOX11 expression and clinical stage. (F–I) Correlation between SOX11 expression and tumor status.
Figure 5. Correlation between SOX11 expression and Clinicopathological Phenotype. (A–E) Correlation between SOX11 expression and clinical stage. (F–I) Correlation between SOX11 expression and tumor status.
Cancers 14 06103 g005
Cancers 14 06103 g006 550
Figure 6. Pan-cancer SOX11 alterations from The Cancer Genome Atlas (TCGA). (A) OncoPrint visual summary of SOX11 alterations in TCGA pan-cancer datasets. Four types of genetic alterations were defined: Missense Mutation (unknown significance), Truncating Mutation (unknown significance), Amplification and Deep Deletion (B) A comprehensive view of the alteration frequency of SOX11 in TCGA pan-cancer datasets. “+” represents that the dataset contained the indicated data. (C) Analysis of the mutation sites and mutation types in SOX11. (D) OncoPrint summary of the alterations on SOX11 in TCGA BRCA dataset. Four types of genetic alterations were defined: Missense Mutation (unknown significance), Amplification, mRNA high and Deep Deletion (E) Kaplan–Meier analysis of disease-free survival in TCGA BRCA cohort with altered or unaltered SOX11. (F) Kaplan–Meier analysis of disease-specific survival in TCGA BRCA cohort with altered or unaltered SOX11.
Figure 6. Pan-cancer SOX11 alterations from The Cancer Genome Atlas (TCGA). (A) OncoPrint visual summary of SOX11 alterations in TCGA pan-cancer datasets. Four types of genetic alterations were defined: Missense Mutation (unknown significance), Truncating Mutation (unknown significance), Amplification and Deep Deletion (B) A comprehensive view of the alteration frequency of SOX11 in TCGA pan-cancer datasets. “+” represents that the dataset contained the indicated data. (C) Analysis of the mutation sites and mutation types in SOX11. (D) OncoPrint summary of the alterations on SOX11 in TCGA BRCA dataset. Four types of genetic alterations were defined: Missense Mutation (unknown significance), Amplification, mRNA high and Deep Deletion (E) Kaplan–Meier analysis of disease-free survival in TCGA BRCA cohort with altered or unaltered SOX11. (F) Kaplan–Meier analysis of disease-specific survival in TCGA BRCA cohort with altered or unaltered SOX11.
Cancers 14 06103 g006
Cancers 14 06103 g007 550
Figure 7. Analysis of the relationship between SOX11 expression and stemness and EMT-related genes in cancers. (A) The correlation between SOX11 expression and DNAss in different cancers. The red dots indicate positive correlations, while the blue dots denote negative correlations. DNAss, DNA stemness score (B) The correlation between SOX11 expression and RNAss in different cancers. RNAss, RNA stemness score (C) Correlation heatmap showing the relationship between SOX11 expression and EMT-related genes expression. For each pair, the top left triangle indicates the p-value, and the bottom right triangle denotes the correlation coefficient. (D) Correlation heatmap showing the relationship between SOX11 expression and cancer stem cell markers * p < 0.05, ** p < 0.01, and *** p < 0.001. Cor, correlation coefficient.
Figure 7. Analysis of the relationship between SOX11 expression and stemness and EMT-related genes in cancers. (A) The correlation between SOX11 expression and DNAss in different cancers. The red dots indicate positive correlations, while the blue dots denote negative correlations. DNAss, DNA stemness score (B) The correlation between SOX11 expression and RNAss in different cancers. RNAss, RNA stemness score (C) Correlation heatmap showing the relationship between SOX11 expression and EMT-related genes expression. For each pair, the top left triangle indicates the p-value, and the bottom right triangle denotes the correlation coefficient. (D) Correlation heatmap showing the relationship between SOX11 expression and cancer stem cell markers * p < 0.05, ** p < 0.01, and *** p < 0.001. Cor, correlation coefficient.
Cancers 14 06103 g007
Cancers 14 06103 g008 550
Figure 8. Analysis of the associations of SOX11 expression with TMB, MSI and MMR genes. (A) Radar map reflecting the correlation between the SOX11 expression and TMB. (B) Radar map reflecting the correlation between the SOX11 expression and MSI. (C) Correlation heatmap showing the relationship between SOX11 expression and MMR genes. For each pair, the top left triangle indicates the p-value, and the bottom right triangle denotes the correlation coefficient * p < 0.05, ** p < 0.01, and *** p < 0.001. Cor, correlation coefficient.
Figure 8. Analysis of the associations of SOX11 expression with TMB, MSI and MMR genes. (A) Radar map reflecting the correlation between the SOX11 expression and TMB. (B) Radar map reflecting the correlation between the SOX11 expression and MSI. (C) Correlation heatmap showing the relationship between SOX11 expression and MMR genes. For each pair, the top left triangle indicates the p-value, and the bottom right triangle denotes the correlation coefficient * p < 0.05, ** p < 0.01, and *** p < 0.001. Cor, correlation coefficient.
Cancers 14 06103 g008
Cancers 14 06103 g009 550
Figure 9. Analysis of the association of SOX11 gene expression with the immune microenvironment. (A) An analysis of the relationship between SOX11 expression and ESTIMATEScore in different cancers. The red dots indicate a positive correlation, while the blue dots denote indicate a negative correlation. (B) Correlation between the SOX11 expression and ImmuneScore in different cancers. (C–I) Correlation between CD8+ T cell infiltration and SOX11 expression in COAD, HNSC, LUAD, PAAD, SKCM, THCA and THYM.
Figure 9. Analysis of the association of SOX11 gene expression with the immune microenvironment. (A) An analysis of the relationship between SOX11 expression and ESTIMATEScore in different cancers. The red dots indicate a positive correlation, while the blue dots denote indicate a negative correlation. (B) Correlation between the SOX11 expression and ImmuneScore in different cancers. (C–I) Correlation between CD8+ T cell infiltration and SOX11 expression in COAD, HNSC, LUAD, PAAD, SKCM, THCA and THYM.
Cancers 14 06103 g009
Cancers 14 06103 g010 550
Figure 10. The Gene Set Enrichment Analysis (GSEA) in Kyoto Encyclopedia of Genes and Genomes (KEGG) signature of GBM, HNSC, KIRC, LUSC, OV, PAAD, PRAD and STAD. The curves with different colors indicate the different pathway annotations. Peaks in the upward direction indicate positive regulation by SOX11 and peaks in the downward direction represent negative regulation by SOX11. (A) The GSEA analysis of SOX11-mediated biological process in GBM; (B) The GSEA analysis of SOX11-mediated biological process in HNSC; (C) The GSEA analysis of SOX11-mediated biological process in KIRC; (D) The GSEA analysis of SOX11-mediated biological process in LUSC; (E) The GSEA analysis of SOX11-mediated biological process in OV; (F) The GSEA analysis of SOX11-mediated biological process in PAAD; (G) The GSEA analysis of SOX11-mediated biological process in PRAD; (H) The GSEA analysis of SOX11-mediated biological process in STAD.
Figure 10. The Gene Set Enrichment Analysis (GSEA) in Kyoto Encyclopedia of Genes and Genomes (KEGG) signature of GBM, HNSC, KIRC, LUSC, OV, PAAD, PRAD and STAD. The curves with different colors indicate the different pathway annotations. Peaks in the upward direction indicate positive regulation by SOX11 and peaks in the downward direction represent negative regulation by SOX11. (A) The GSEA analysis of SOX11-mediated biological process in GBM; (B) The GSEA analysis of SOX11-mediated biological process in HNSC; (C) The GSEA analysis of SOX11-mediated biological process in KIRC; (D) The GSEA analysis of SOX11-mediated biological process in LUSC; (E) The GSEA analysis of SOX11-mediated biological process in OV; (F) The GSEA analysis of SOX11-mediated biological process in PAAD; (G) The GSEA analysis of SOX11-mediated biological process in PRAD; (H) The GSEA analysis of SOX11-mediated biological process in STAD.
Cancers 14 06103 g010
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Sun, Q.; Du, J.; Dong, J.; Pan, S.; Jin, H.; Han, X.; Zhang, J. Systematic Investigation of the Multifaceted Role of SOX11 in Cancer. Cancers 2022, 14, 6103. https://doi.org/10.3390/cancers14246103

AMA Style

Sun Q, Du J, Dong J, Pan S, Jin H, Han X, Zhang J. Systematic Investigation of the Multifaceted Role of SOX11 in Cancer. Cancers. 2022; 14(24):6103. https://doi.org/10.3390/cancers14246103

Chicago/Turabian Style

Sun, Qingqing, Jun Du, Jie Dong, Shuaikang Pan, Hongwei Jin, Xinghua Han, and Jinguo Zhang. 2022. "Systematic Investigation of the Multifaceted Role of SOX11 in Cancer" Cancers 14, no. 24: 6103. https://doi.org/10.3390/cancers14246103

APA Style

Sun, Q., Du, J., Dong, J., Pan, S., Jin, H., Han, X., & Zhang, J. (2022). Systematic Investigation of the Multifaceted Role of SOX11 in Cancer. Cancers, 14(24), 6103. https://doi.org/10.3390/cancers14246103

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop